🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesNNT for MACE prevention — July 2024

NNT for MACE prevention — July 2024

gary_naperville Tue, Dec 17, 2024 at 10:59 AM 36 replies 1,910 viewsPage 1 of 8
This thread is more than 17 months old. Information may be outdated. Consider searching for more recent discussions.
gary_naperville
Member
245
1,123
Oct 2024
Naperville, IL
Dec 17, 2024 at 10:59 AM#1

My reason for being on this is cardiovascular rather than cosmetic, which puts me in a small minority in most of these threads.

What would genuinely help is knowing how much of the SELECT benefit is plausibly independent of the weight loss, and whether that distinction changes anything practical.

Tell me what I have not thought of.

9 12SleepFixSam, PurityPaulOR, MaxMetOK and 6 others
Reply Quote Save Share Report
FDA_TrackerJim
Senior Member
1,567
7,890
Feb 2024
Rockville, MD
Dec 17, 2024 at 11:34 AM#2
gary_naperville said:
My reason for being on this is cardiovascular rather than cosmetic, which puts me in a small minority in most of these threads.

I'm 62 years old and want to share my perspective on cardiovascular risk as an older member of this community.

My doctor was initially hesitant because of my age, but the SELECT trial included patients up to 72 and showed consistent benefit across age groups. We started at the lowest dose with closer monitoring.

9 months later: down 46 lbs, off atorvastatin, A1C from 7.2% to 5.3%. My cardiologist is thrilled. cardiovascular risk is absolutely relevant for older adults — don't let anyone tell you otherwise.

Last edited: Dec 17, 2024 at 2:34 PM
10 13Admin, Dr.Martinez, mike_mod and 7 others
Reply Quote Save Share Report
nick_newbie
New Member
18
56
Jun 2026
Virginia
Online
Dec 17, 2024 at 12:09 PM#3
FDA_TrackerJim said:
I'm 62 years old and want to share my perspective on cardiovascular risk as an older member of this community.

SUSTAIN-6 was the first CVOT to show cardiovascular benefit with semaglutide, relevant to cardiovascular risk. In 3,297 T2DM patients with high CV risk: MACE HR 0.74 (95% CI 0.58-0.95, p=0.02)[1].

Notable: the retinopathy signal in SUSTAIN-6 (HR 1.76) was subsequently attributed to rapid A1C reduction in patients with pre-existing retinopathy — not a direct drug effect. This has been confirmed in longer-term follow-up studies.

References:
[1] Marso SP, et al. N Engl J Med. 2016;375(19):1834-1844.
Last edited: Dec 17, 2024 at 3:09 PM
11 14MeganSA_TX, LarryQC_SD, wanda_boise and 8 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
DoseLogDan
Member
201
567
Feb 2025
Montana
Dec 17, 2024 at 12:44 PM#4
gary_naperville said:
My reason for being on this is cardiovascular rather than cosmetic, which puts me in a small minority in most of these threads.

Same experience, arrived at from the opposite direction.

Last edited: Dec 17, 2024 at 1:44 PM
12 15sophie_paris, mel_PDX, Dr.AddMedPHL and 9 others
Reply Quote Save Share Report
Dr.LeslieOBGYN
Member
567
2,567
May 2024
Dallas, TX
Dec 17, 2024 at 3:58 PM#5

Clinical perspective, offered as context rather than as advice.

gary_naperville said:
...we're creating a generation dependent on cardiovascular risk...

I understand the concern, but consider this analogy: are we "creating a generation dependent on" blood pressure medication? Cholesterol medication? Thyroid medication?

Obesity is a chronic disease with biological drivers. Treating it with medication is no different from treating any other chronic condition. The "dependency" framing implies weakness or moral failure — neither of which is accurate.

If ongoing medication is what keeps someone healthy, that's successful treatment, not dependency.

Last edited: Dec 17, 2024 at 9:58 PM
13 16mike_mealprep, NicoleRaleigh, james_edin and 10 others
Reply Quote Save Share Report
1238

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register